InvestSMART

Firebrick Pharma Limited (ASX:FRE)

ALERT: Price-sensitive ASX Announcement for FRE
Current share price for FRE : $0.027 -0.001 (-3.57%)+
Announcement
Release
27 Jul 2026 9:32AM
Price at Release
$0.028
Full Release
download
Summary
Firebrick Pharma Limited's June 2026 Quarterly Activity Report highlights the company receiving two new patents in Canada and New Zealand, and a financial overview showing a slight increase in cash operating expenses to $839k due to pre-payments. Sales for the quarter were $66k, contributing to a total of $227k for FY26, representing 43% growth compared to the previous year. The net cash burn was $768k for the quarter and $2,603k for the fiscal year, with closing cash reserves of $1,322k. Firebrick is actively seeking market approvals for its Nasodine products in additional countries.
Key Points
  • Firebrick Pharma Limited announced the June 2026 Quarterly Activity Report.
  • The company received two new patents during the quarter, one in Canada and one in New Zealand.
  • Cash operating expenses for the June quarter were $839k, slightly higher due to pre-payments.
  • Sales receipts for the quarter were $66k, with annual sales for FY26 totaling $227k, indicating a 43% growth.
  • The net cash burn for the quarter was $768k, with an overall FY26 cash burn of $2,603k.
  • Cash at the end of June 2026 was $1,322k.
  • Firebrick Pharma is pursuing approvals for its Nasodine products in additional international markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.